Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the ability of an empiric resuscitation strategy compared to standard care to decrease the incidence of organ failure in normotensive sepsis patients.
Sepsis is a challenging and elusive entity with a high mortality rate. As a syndrome, clinicians are challenged to distinguish individuals with systemic infection warranting further interventions from lower severity patients. Sepsis is now recognized as a time-sensitive emergency, as patients stand the best chance for survival when effective therapeutic interventions are delivered as early as possible.
Recent data has shown that in-hospital disease progression from sepsis to septic shock is associated with a higher risk of morbidity and mortality than those with shock on initial presentation. Yet, even when identified and treated with early aggressive interventions, the development of septic shock is still associated with a mortality rate of 25-40%.
Although the presence of sustained arterial hypotension or serum lactate elevation (>4.0 mmol/L) are the currently recommended threshold to define the presence of overt shock and the need for aggressive resuscitation, the investigators have shown that, in patients with systemic infection, a moderate lactate elevation (2.0-3.9 mmol/L) is a common occurrence and an important warning sign for the increased risk of disease progression and death. Sepsis with an elevated lactate between 2.0-3.9, referred to as the "PRE-SHOCK" state, identifies this population of patients at-risk for poor outcome. Current guidelines for sepsis management do not recommend any specific resuscitation measures or therapies for this at-risk population. This study marks the first in a series of investigations addressing the PRE-SHOCK population to further define the adverse events within this cohort and to investigate novel interventions to improve outcomes.
The investigators hypothesize that an early quantitative resuscitation strategy using a protocol-directed IV fluid resuscitation will result in a significant reduction in the development of worsening organ failure (including shock) and mortality compared to standard care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | Standard medical care by the primary treatment team. | |
| Interventional arm | Experimental | Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravenous fluid | Drug | 0.9% Sodium chloride intravenous fluid |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1 | Development of worsening organ failure defined by the Sequential Organ Failure Assessment (SOFA) score. The SOFA score defines the presence and severity of dysfunction within 6 organ systems (cardiovascular, respiratory, coagulation, liver, renal, and nervous system) with a value of "0" for assigned to normal function to a maximum value of "4" for severe dysfunction in each of the organ systems. Each component of the SOFA score is added together, ranging from "0" indicating no organ dysfunction in any of the 6 organ systems, to "24" indicating maximal organ dysfunction across all 6 organ systems. Within this trial, the occurrence of organ failure was defined by any increase in the total SOFA score by ≥ 1 point over the first 72 hours after randomization. | 72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| In-hospital Mortality | Any occurrence of mortality while the participant is in-hospital is counted as an outcome. | In-hospital discharge or up to maximum 30 days |
| Number of Participants With Experiencing Complications Related to Intravascular Volume Overload |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alan Jones, MD | University of Mississippi Medical Center | Study Chair |
| Ryan Arnold, MD | Cooper University Hospital: Cooper Medical School of Rowan University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Christiana Care Health System | Newark | Delaware | 19718 | United States | ||
| Beth Israel Deaconess Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18092378 | Background | Sakr Y, Vincent JL, Schuerholz T, Filipescu D, Romain A, Hjelmqvist H, Reinhart K. Early- versus late-onset shock in European intensive care units. Shock. 2007 Dec;28(6):636-643. | |
| 19325467 | Background | Mikkelsen ME, Miltiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009 May;37(5):1670-7. doi: 10.1097/CCM.0b013e31819fcf68. |
Not provided
Not provided
Prior to interventional arm of the trial, a 5-month observational period was performed identifying 94 patients in the control arm. At the initiation of the interventional study, subjects were randomized in a 2:1 ratio to intervention:control, enrolling an additional 18 patients to the control arm, and 30 patients to the intervention.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Control | Standard medical care by the primary treatment team. |
| FG001 | Interventional Arm | Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization Intravenous fluid: 0.9% Sodium chloride intravenous fluid |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Control | Standard medical care by the primary treatment team. |
| BG001 | Interventional Arm | Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization Intravenous fluid: 0.9% Sodium chloride intravenous fluid |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1 | Development of worsening organ failure defined by the Sequential Organ Failure Assessment (SOFA) score. The SOFA score defines the presence and severity of dysfunction within 6 organ systems (cardiovascular, respiratory, coagulation, liver, renal, and nervous system) with a value of "0" for assigned to normal function to a maximum value of "4" for severe dysfunction in each of the organ systems. Each component of the SOFA score is added together, ranging from "0" indicating no organ dysfunction in any of the 6 organ systems, to "24" indicating maximal organ dysfunction across all 6 organ systems. Within this trial, the occurrence of organ failure was defined by any increase in the total SOFA score by ≥ 1 point over the first 72 hours after randomization. | Posted | Count of Participants | Participants | 72 hours |
|
Respiratory failure occurring within 24 hours of enrollment. Fluid overload occurring within 24 hours of enrollment. Mortality occurring at anytime within hospital stay.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Control | Standard medical care by the primary treatment team. | 4 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Respiratory failure requiring mechanical intervention | Respiratory, thoracic and mediastinal disorders | Systematic Assessment | Any mechanical ventilation within 24 hours of enrollment. |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ryan Arnold, MD, Director of Research, Emergency Medicine | Christiana Care Health System | 302-733-5108 | ryarnold@christianacare.org |
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D009102 | Multiple Organ Failure |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Composite safety endpoint:
|
| 12 hours following treatment initiation |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| Detroit Receiving Hospital/University Health Center | Detroit | Michigan | 48201 | United States |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | United States |
| Cooper University Hospital:Cooper Medical School of Rowan University | Camden | New Jersey | 08103 | United States |
| 20370777 | Background | Glickman SW, Cairns CB, Otero RM, Woods CW, Tsalik EL, Langley RJ, van Velkinburgh JC, Park LP, Glickman LT, Fowler VG Jr, Kingsmore SF, Rivers EP. Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis. Acad Emerg Med. 2010 Apr;17(4):383-90. doi: 10.1111/j.1553-2712.2010.00664.x. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
Standard medical care by the primary treatment team.
| OG001 | Interventional Arm | Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization Intravenous fluid: 0.9% Sodium chloride intravenous fluid |
|
|
|
| Secondary | In-hospital Mortality | Any occurrence of mortality while the participant is in-hospital is counted as an outcome. | Posted | Count of Participants | Participants | In-hospital discharge or up to maximum 30 days |
|
|
|
| Secondary | Number of Participants With Experiencing Complications Related to Intravascular Volume Overload | Composite safety endpoint:
| Posted | Count of Participants | Participants | 12 hours following treatment initiation |
|
|
|
| 112 |
| 4 |
| 112 |
| 0 |
| 112 |
| EG001 | Interventional Arm | Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization Intravenous fluid: 0.9% Sodium chloride intravenous fluid | 0 | 30 | 3 | 30 | 0 | 30 |
|
| Intravascular fluid overload | Vascular disorders | Systematic Assessment | Assessment by treating physician of intravascular fluid overload |
|
| Mortality | General disorders | Systematic Assessment | All cause in-hospital mortality |
|
Not provided
Not provided
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |